Skip to main content

Table 3 Tumor growth inhibition in A549 xenograft model

From: A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

Drugs Mean Tumor Volume Growth inhibition (TGI%) P value vs PBS P value vs Bevacizumab
HB-002.1, 5 mg/kg 2.72 (2.51-2.91) 78.02 <0.0001 <0.0001
HB-002.1, 20 mg/kg 1.89 (1.66-2.16) 84.71 <0.0001 <0.0001
Bevacizumab, 5 mg/kg 4.40 (3.59-5.40) 64.46 <0.0001 NA
Bevacizumab, 20 mg/kg 4.02 (3.36-4.81) 67.55 <0.0001 NA
PBS 12.38 (9.87-15.54) 0.00 NA NA
  1. Sample size = 10 for each group.
  2. Mean Tumor Volume = geometric mean with 95% confidence interval in parentheses. Geometric mean is shown because statistical analyses utilized log-transformed data that best modeled tumor volume growth.
  3. P value was calculated as described in Methods.
  4. P value vs Bevacizumab is compared to same dose of HB-002.1.
  5. NA = not applicable.
\